Page 233 - 2021_09-Haematologica-web
P. 233
Letters to the Editor
tiple myeloma treatment. Blood. 2018;132(25):2656-2669.
10. Seiller C, Maiga S, Touzeau C, et al. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX / BAK hetero-
complexes. Cell Death Dis. 2020;11(5):316.
11. Wilson WH, Connor OAO, Czuczman MS, et al. Navitoclax , a
targeted high-affi nity inhibitor of BCL-2 , in lymphoid malig- nancies: a phase 1 dose-escalation study of safety , pharmacoki- netics , pharmacodynamics, and antitumour activity. Lancet Oncol. 2010; 11(12):1149-1159.
12. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anu-
clear cell death delimits platelet life span. Cell. 2007;128(6):1173-
1186.
13. Santo L, Hideshima T, Kung AL, et al. Preclinical activity , phar-
macodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215 , in combination with bortezomib in multiple myeloma. Blood. 2019;119(11):2579-2590.
14.Carew JS, Espitia CM, Zhao W, et al. Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activi- ty. Blood Adv. 2019;3(8):1318-1329.
15. Hubbert C, Guardiola A, Shao R. HDAC6 is a microtubule-asso- ciated deacetylase. Nature. 2002;417(6887):455-458.
haematologica | 2021; 106(9)
2521
